Hyperosmotic stress contributes to mouse colonic inflammation through the methylation of protein phosphatase 2A

Laurent Schwartz1, Mohammad Abolhassani, Mohammad Pooya

  • 1Service de Radiothérapie Hôpital Pitié-Salpétrière, bd. de l'Hôpital, 75013 Paris, France. laurent.schwartz@polytechnique.edu

Insights

Hyperosmolarity in the gut, such as from dextran sulfate sodium (DSS), causes inflammatory bowel disease (IBD) by activating protein phosphatase 2A (PP2A). Inhibiting PP2A can reverse this inflammation.

Area of Science:

  • Gastroenterology
  • Molecular Biology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) is linked to hyperosmotic fecal content.
  • Hyperosmolarity is known to induce inflammation via protein phosphatase 2A (PP2A) methylation and NF-kappaB activation.

Purpose of the Study:

  • To investigate the role of hyperosmolarity and PP2A activation in dextran sulfate sodium (DSS)-induced colitis.
  • To explore potential therapeutic targets for DSS-induced chronic colitis.

Main Methods:

  • Mice were administered varying concentrations of DSS or mannitol orally for 3 or 12 weeks.
  • Assessed colonic inflammation, sacral lymph node weight, serum amyloid A levels.
  • Investigated the effects of a PP2A inhibitor (okadaic acid) and siRNAs targeting PP2Ac.

Main Results:

  • Hyperosmotic DSS and mannitol significantly increased colonic inflammation, lymph node weight, and serum amyloid A.
  • Hyperosmolarity led to PP2A methylation, NF-kappaB activation, and cytokine secretion.
  • Okadaic acid and PP2Ac-targeting siRNAs reversed DSS-induced colitis.

Conclusions:

  • DSS-induced chronic colitis is caused by hyperosmolarity-induced methylation of PP2Ac.
  • PP2A activation is a key mechanism in hyperosmolarity-driven gut inflammation.
  • Targeting PP2A may offer a therapeutic strategy for IBD.